The authors report on six pediatric liver transplant recipients for whom allograft tolerance occurred shortly after transplantation (ie, less than 1.5 years). All the patients had associated life-threatening viral complications. They are currently immunocompetent. The tolerant state may be related to the development of a TH 2 cytokine pattern.
Index WordsLiver transplantation; allograft Development of a drug-free state has long been an aspiration in transplantation. It is particularly desirable in children because they are subject to complications secondary to the lifelong administration of immunosuppressive agents. We report on a small group of pediatric patients who in the presence of life-threatening complications had allograft tolerance shortly after transplantation. The immune unresponsiveness appeared to be donor-specific. They were shown to be otherwise immunocompetent.
Materials and Methods
Case MaterialAmong our pediatric transplant population (liver, kidney, intestinal, and pancreatic islet recipients), there were six patients (Table 1) who had life-threatening viral infections not long after transplantation but also had tolerance to their grafts. All the patients were liver transplant recipients treated with FK-506-based immunosuppression. 1 The age range at the time of transplantation was 0.3 to 1.5 years. The primary disease was biliary atresia (3), neonatal hepatitis (1), fulminant hepatitis C (1), or cat's eye syndrome (1). Posttransplant, three of them had one or more episodes of acute rejection that required treatment with steroids, and three had no rejection at all.The complications that necessitated discontinuation of the immunosuppression were lymphoproliferative disease (PTLD) (n = 5) and severe hepatitis C (n = 2). Patient no. 4 had both complications. Hepatitis was recurrent in one case and acquired after transplantation in the other. Immunosuppression was discontinued 0.5 to 1.3 years posttransplantation, and, to date (1.3 to 2.8 years later), it has not been resumed.
NIH-PA Author ManuscriptNIH-PA Author Manuscript
NIH-PA Author ManuscriptOne patient died after retransplantation for hepatitis C. All others are alive with the same grafts. PTLD and hepatitis C have been controlled successfully in all surviving patients. There have been no other severe infections. All patients are rejection-free; this was demonstrated clinically, biochemically, and histologically.Another patient (no. 7, Table 1), a 1-year-old girl who received a liver allograft under FK-506 for biliary atresia, had severe hepatitis C 2 years after transplantation, and the immunosuppression was withdrawn. She remained rejection-free for 0.9 years. Rejection then developed, which required resumption of FK-506. The patient still has evidence of active hepatitis C.
In Vitro Immunologic StudiesThese tests were done to evaluate immune competence. Functional evaluation of T helper cells was performed by measuring the ability of peripheral blood lymphocytes (PBL) to proliferate in response to nonspecific plant lectins: phy...